Search
Adagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigationalKRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. … [A254052] In a phase I/IB clinical study that included patients with KRAS<sup>G12C</sup>-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity.
Anethole trithione
go.drugbank.com/drugs/DB13853Approvedhepatitis [L2388] and is marketed in certain countries like France, Germany, and China [A32614]. … have yet to be formally elucidated, which means that while studies are ongoing, ATT itself is not necessarily formally indicated for many of these aforementioned functions at this time and is only used in
Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10780ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Physicians EZ Use Flu Kit, Medical Provider Single Use EZ Flu Shot KitInfluenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10782ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Physicians EZ Use Flu Kit, Medical Provider Single Use EZ Flu Shot KitBamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigationalit in collaboration with Eli Lilly and Company. … [L15316, L15321] Under the EUA granted in February 2021, bamlanivimab is used in combination with [etesevimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk
Simeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawnThe SVR12 was 83% (29/35) in treatment-naïve patients and 86% (19/22) in relapsing patients. … Sustained virologic response 12 weeks after planned end of treatment (SVR12) was achieved in 170/176 (97%) subjects without cirrhosis treated with 12 weeks simeprevir in combination with sofosbuvir (FDA
Clofazimine
go.drugbank.com/drugs/DB00845ApprovedInvestigationalWithdrawnIt was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. … [A203144] Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis
Edoxudine
go.drugbank.com/drugs/DB13421ApprovedWithdrawnIt was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus. … The obtained product is an antiviral ointment.[L2407] The activity of edoxudine against herpes simplex virus was first recognized in 1967.
Benziodarone
go.drugbank.com/drugs/DB13277ApprovedWithdrawnIt is used in the treatment of gout [A175630]. It was withdrawn from France markets and British markets due to its effects causing Jaundice in patients [T487, A175636].
Categories: Vasodilators Used in Cardiac DiseasesParaldehyde
go.drugbank.com/drugs/DB09117ApprovedWithdrawnParaldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. … Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo